OrbusNeich has showcased its next-generation coronary balloon catheters at AsiaPCR/SingLIVE 2016 in Singapore. The Case-in-Point session, ‘Your complex PCI: How can new technologies enhance procedural success?’, reviewed solutions for calcified lesions with complex anatomy, where the dual-wire Scoreflex balloon can be used as an alternative to rotablation and featured chronic total occlusion (CTO) techniques with the Sapphire II PRO.
Facilitated by Eric Eeckhout, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, and Michael Nguyen, Fiona Stanley Hospital, Perth, Australia, the session reviewed CTO techniques to increase success rates in the most difficult cases, and provided an opportunity for interventional cardiologists to discuss their own experience and share their learnings.
Eeckhout also presented three cases that highlighted the use of specialised tools and techniques in his lecture, ‘Simplifying CTO: the right device selection is critical for success.’ According to an OrbusNeich press release, discussion concluded that while there is debate that balloon technology has reached its optimum performance, there is a new generation of balloons for CTO that is pushing the boundaries of technology, and the Sapphire II PRO is an example of this progress.
The lecture entitled ‘The challenge in tackling complex lesions’ was presented by Paul Ong, Tan Tock Seng Hospital, Singapore, and explored how focused force angioplasty (FFA) devices such as Scoreflex are used in contemporary practice. Scoreflex is a focused force dilatation balloon that comes with a dual wire system, enabling effective dilatation under lower inflation pressure. Ong featured two successful case studies using a Scoreflex for predilation. The first case was an ostial LAD lesion which was treated with a drug-coated balloon (DCB) and the second was a highly calcified lesion that required heavy predilation prior to the implantation of two bioresorbable scaffolds.
“The conclusion message from both case studies was clear that proper lesion preparation using FFA devices, such as Scoreflex, helps increase minimal lumen diameter before drug-coated balloons or the placement of bioresorbable scaffolds,” said Ong. “Lesion preparation with more controlled plaque modification by Scoreflex results in better outcomes.”
“AsiaPCR/SingLIVE 2016 is an exceptional opportunity for us to demonstrate both the excellence of our products and their impact on patients’ lives to the cardiovascular community in a collegiate and informative setting,” says Alain Aimonetti, senior vice president, Global Sales and Marketing, OrbusNeich. “With increasing ageing populations, interventional cardiologists are seeing more complex coronary disease, and we must ensure devices accommodate these more challenging cases to provide patients with the best possible treatment strategies.”
Both the Sapphire II PRO and Scoreflex have been developed by OrbusNeich, a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company is also behind the Combo dual-therapy stent, the first dual therapy stent to accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Pro-Healing technology with an abluminal sirolimus drug elution delivered from a bioresorbable polymer that is completely dissipated within 90 days.